Endocrine Abstracts

Introduction: 131I-Metaiodobenzylguanidine (131I-MIBG) is used as palliative therapy in patients with metastatic neuroendocrine tumours (NET), but can cause bone marrow suppression, hypothyroidism and renal impairment.Methods: Retrospective case note analysis identified 58 patients treated with between May 1996 and May 2006. We assessed the efficacy and toxicity of 131I-MIBG therapy in 49 of these patients (12men; mean age at diagnosis: 57.4 years; range...

Introduction: The beneficial effect of GH replacement on bone in AGHD patients is mediated by improvements in target organ sensitivity to PTH and phosphocalcium metabolism. In aging women with established osteoporosis, GH and IGF-1 concentrations are lower and administration of GH has been shown to increase bone turnover and BMD, but the mechanisms remain unclear.Methods: Fourteen postmenopausal women (63.4±2.1 years; mean BMD T score ± ...

IntroductionPrimary hyperparathyroidism (PHP) due to adenoma or hyperplasia is common and is being increasingly diagnosed. Overall 80% are due to single adenoma, 15% to multiglandular hyperplasia, 3% to multiple adenomata (usually 2) and 2% to carcinoma. In 20-30% the glands will be ectopically placed, usually within the neck, though can be anywhere from the skull base to the diaphragm.Surgery is the treatment and a longterm debate...

BACKGROUD: Parathyroid hormone (PTH) is normally secreted in a circadian rhythm and modulates bone turnover through the differential stimulation of receptor activator for nuclear factor kappa-B ligand (RANKL) and suppression of osteoprotegerin (OPG), both of which are fundamental factors in regulating bone turnover. We have studied the relationship between PTH and OPG over a 24-hour period.METHODS: Hourly peripheral venous blood samples were obtained fro...